中国医刊
中國醫刊
중국의간
CHINESE JOURNAL OF MEDICINE
2015年
6期
41-44
,共4页
华秀芬%吴娜%许君%许毛宇
華秀芬%吳娜%許君%許毛宇
화수분%오나%허군%허모우
支原体肺炎%哌拉西林舒巴坦%阿奇霉素%免疫力
支原體肺炎%哌拉西林舒巴坦%阿奇黴素%免疫力
지원체폐염%고랍서림서파탄%아기매소%면역력
Mycoplasma pneumoniae pneumonia%Piperacillin-tazobactam%Azithromycin%Immunity
目的观察哌拉西林舒巴坦联合阿奇霉素治疗重症儿童支原体肺炎的临床疗效,评估其对机体免疫力的影响。方法选取2011年3月至2014年6月在浙江省杭州市儿童医院就诊的重症支原体肺炎患儿84例,随机分为两组。对照组以10mg/kg的标准单用阿奇霉素治疗,试验组在应用同等剂量的阿奇霉素的基础上,加用哌拉西林舒巴坦40mg/kg治疗。结果试验组总有效率为95.24%,对照组为80.95%,试验组总有效率明显高于对照组(字2=5.126,P=0.024)。试验组患儿退热时间、咳嗽消失时间、肺部啰音消失时间、住院时间与对照组相比差异有显著性( t=5.752,P<0.001；t=3.180,P=0.002；t=2.274,P=0.009；t=4.201,P<0.001)。治疗后,免疫球蛋白及T细胞亚群的水平均明显升高(P<0.05),且试验组比对照组升高更为明显(P<0.05)。结论哌拉西林舒巴坦联合阿奇霉素对重症支原体肺炎具有良好的治疗效果,值得进一步在临床应用。
目的觀察哌拉西林舒巴坦聯閤阿奇黴素治療重癥兒童支原體肺炎的臨床療效,評估其對機體免疫力的影響。方法選取2011年3月至2014年6月在浙江省杭州市兒童醫院就診的重癥支原體肺炎患兒84例,隨機分為兩組。對照組以10mg/kg的標準單用阿奇黴素治療,試驗組在應用同等劑量的阿奇黴素的基礎上,加用哌拉西林舒巴坦40mg/kg治療。結果試驗組總有效率為95.24%,對照組為80.95%,試驗組總有效率明顯高于對照組(字2=5.126,P=0.024)。試驗組患兒退熱時間、咳嗽消失時間、肺部啰音消失時間、住院時間與對照組相比差異有顯著性( t=5.752,P<0.001；t=3.180,P=0.002；t=2.274,P=0.009；t=4.201,P<0.001)。治療後,免疫毬蛋白及T細胞亞群的水平均明顯升高(P<0.05),且試驗組比對照組升高更為明顯(P<0.05)。結論哌拉西林舒巴坦聯閤阿奇黴素對重癥支原體肺炎具有良好的治療效果,值得進一步在臨床應用。
목적관찰고랍서림서파탄연합아기매소치료중증인동지원체폐염적림상료효,평고기대궤체면역력적영향。방법선취2011년3월지2014년6월재절강성항주시인동의원취진적중증지원체폐염환인84례,수궤분위량조。대조조이10mg/kg적표준단용아기매소치료,시험조재응용동등제량적아기매소적기출상,가용고랍서림서파탄40mg/kg치료。결과시험조총유효솔위95.24%,대조조위80.95%,시험조총유효솔명현고우대조조(자2=5.126,P=0.024)。시험조환인퇴열시간、해수소실시간、폐부라음소실시간、주원시간여대조조상비차이유현저성( t=5.752,P<0.001；t=3.180,P=0.002；t=2.274,P=0.009；t=4.201,P<0.001)。치료후,면역구단백급T세포아군적수평균명현승고(P<0.05),차시험조비대조조승고경위명현(P<0.05)。결론고랍서림서파탄연합아기매소대중증지원체폐염구유량호적치료효과,치득진일보재림상응용。
Objective To observe the therapeutic effect of piperacillin-tazobactam combined with azithromycin in the treatment of severe Mycoplasma pneumoniae pneumonia in children and their effect on immunity. Method To select the clinical data of patients undergoing severe Mycoplasma pneumoniae pneumonia admitted to our hospital from March 2011 to June 2014, and 84 patients were admitted. They were randomly divided into 2 groups. Group 1 was treated with piperacillin-tazobactam combined with azithromycin, while group 2 was treated with azithromycin only. Both groups were treated for 14 days. Result The effective rate of group 1 was 95. 24%, which was significantly higher than that of group 2(80. 95%, P=0. 024). There was a significant difference between two groups (t=5. 752, P<0. 001;t=3. 180, P=0. 002; t=2. 274, P=0. 009; t=4. 201, P<0. 001). There was no difference between two groups in immunoglobulin ( IgA, IgG, IgM) and T cell sub-group ( CD3+, CD4+, CD8+) levels before treatment (P>0. 05). After the treatment, and they all increased in both groups (P<0. 05), but group 1 increased significantly more than group 1 (P<0. 05). Conclusion Piperacillin-tazobactam combined with azithromycin in the treatment of severe mycoplasma pneumoniae pneumonia can get better therapeutic efficacy with no more adverse reaction.
